Premium
Gene Polymorphisms of the Mu Opioid Receptor in Methamphetamine Abusers
Author(s) -
IDE SOICHIRO,
KOBAYASHI HIDEAKI,
TANAKA KEIKO,
UJIKE HIROSHI,
SEKINE YOSHIMOTO,
OZAKI NORIO,
INADA TOSHIYA,
HARANO MUTSUO,
KOMIYAMA TOKUTARO,
YAMADA MITSUHIKO,
IYO MASAOMI,
IKEDA KAZUTAKA,
SORA ICHIRO
Publication year - 2004
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1316.039
Subject(s) - methamphetamine , single nucleotide polymorphism , genetics , genotype , allele , psychosis , population , allele frequency , biology , snp , polymorphism (computer science) , medicine , gene , pharmacology , psychiatry , environmental health
A bstract : In drug addiction, the opioid system is thought to mediate motivational effects through dopamine‐independent mechanisms. We have investigated associations of the μ‐opioid receptor gene (OPRM) variations with methamphetamine (MAP) dependence/psychosis. The allelic frequency of A118G (Asn40Asp) in exon 1 of ORPM was 45.3% in our control subjects, but only 7.5‐25.8% in the Caucasian or African‐American population of previous studies. We have identified several novel polymorphisms in intron 1 and the 5′ untranslated region (5′UTR) of OPRM. Polymorphisms in the functionally relevant 5′ regulatory region of OPRM were different in our Japanese population from Caucasian or African‐American populations. No significant differences between controls and MAP abusers were found in either genotype or allele frequency at any single nucleotide polymorphism (SNP) or (AC)n dinucleotide repeat in intron 1. A subdivision of our MAP group revealed that A118G of OPRM shows a significant association with MAP psychosis having latency less than three years. Further analysis should be capable of identifying associations between the OPRM variations and MAP dependence/psychosis.